Utilize este identificador para referenciar este registo:
https://hdl.handle.net/1822/57171
Registo completo
Campo DC | Valor | Idioma |
---|---|---|
dc.contributor.author | Tinoco, Ana Catarina Malheiro | por |
dc.contributor.author | Passos, Marisa Sárria Pereira | por |
dc.contributor.author | Loureiro, Ana Isabel Sá | por |
dc.contributor.author | Parpot, Pier | por |
dc.contributor.author | Espiña, Begoña | por |
dc.contributor.author | Gomes, Andreia C | por |
dc.contributor.author | Cavaco-Paulo, Artur | por |
dc.contributor.author | Ribeiro, Artur | por |
dc.date.accessioned | 2018-12-07T08:43:11Z | - |
dc.date.available | 2018-12-07T08:43:11Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Tinoco, Ana Catarina; Sárria, Marisa P.; Loureiro, Ana; Parpot, Pier; Espiña, Begoña; Gomes, Andreia C.; Cavaco-Paulo, Artur; Ribeiro, Artur, BSA/ASN/Pol407 nanoparticles for Acute Lymphoblastic Leukemia treatment. Biochemical Engineering Journal, 141, 80-88, 2019 | por |
dc.identifier.issn | 1369-703X | por |
dc.identifier.uri | https://hdl.handle.net/1822/57171 | - |
dc.description.abstract | During the treatment of acute lymphoblastic leukemia (ALL) with asparaginase (ASN) there is an accumulation of ammonia in the body as result of asparagine hydrolysis. This accumulation known as hyperammonemia is one of the main side-effects of this therapy. To avoid hyperammonemia is urgent to develop new strategies for ammonia retention. Herein is presented the immobilization of ASN into bovine serum albumin/poloxamer 407 (BSA/Pol407) nanoparticles. The ability of the developed nanoparticles to hydrolyze asparagine while retaining the forming ammonia is also explored. Different percentages of ASN were entrapped into BSA nanoparticles coated with Poloxamer 407 and were prepared by high-pressure homogenization. The nanoparticles were characterized regarding their physico-chemical properties, stability, capacity to retain ammonia and safety using zebrafish embryos as an in vivo model of toxicity. The BSA/ASN25%/Pol407 nanoparticles were selected as the best formulation to hydrolyze asparagine using the lowest nanoparticle concentration. These nanoparticles presented physical characteristics suitable for an intravenous application and were capable to retain the forming ammonia decreasing the negative effect of free ASN on zebrafish survival. These nanoparticles could potentially be used to prevent hyperammonemia during ALL treatment with ASN. | por |
dc.description.sponsorship | This study was supported by FCT under the scope of the strategic funding of UID/BIO/04469/2013 unit and COMPETE 2020 (POCI-01- 0145-FEDER-006684) and BioTecNorte operation (NORTE-01-0145- FEDER-000004) and Nanotechnology Based Functional Solutions (NORTE-01-0145-FEDER-000019) funded by the European Regional Development Fund under the scope of Norte2020 - Programa Operacional Regional do Norte. We also acknowledge the strategic programme UID/BIA/04050/2013 (POCI-01-0145-FEDER-007569) funded by national funds through Fundação para a Ciência e a Tecnologia (FCT) and by the ERDF through the COMPETE2020 - Programa Operacional Competitividade e Internacionalização (POCI). Marisa P. Sárria was supported by Marie Curie COFUND funding from the European Union’s 7th Framework Programme for research, technological development and demonstration under grant agreement 600,375. Artur Ribeiro and Ana Tinoco thanks FCT for funding the scholarships with the references SFRH/BPD/98388/2013, SFRH/BD/ 114035/2015, respectively. | por |
dc.language.iso | eng | por |
dc.publisher | Elsevier 1 | por |
dc.relation | info:eu-repo/grantAgreement/FCT/5876/147337/PT | por |
dc.relation | info:eu-repo/grantAgreement/FCT/5876/147364/PT | por |
dc.relation | info:eu-repo/grantAgreement/FCT/SFRH/SFRH%2FBPD%2F98388%2F2013/PT | por |
dc.rights | openAccess | por |
dc.subject | Asparaginase | por |
dc.subject | Nanoparticle | por |
dc.subject | Acute Lymphoblastic Leukemia | por |
dc.subject | Hyperammonemia | por |
dc.subject | Ammonia Retention | por |
dc.subject | ZET Assay | por |
dc.title | BSA/ASN/Pol407 nanoparticles for acute lymphoblastic leukemia treatment | por |
dc.type | article | - |
dc.peerreviewed | yes | por |
dc.relation.publisherversion | http://www.elsevier.com/locate/issn/1369703X | por |
dc.comments | CEB48989 | por |
oaire.citationStartPage | 80 | por |
oaire.citationEndPage | 88 | por |
oaire.citationConferencePlace | Netherlands | - |
oaire.citationVolume | 141 | por |
dc.date.updated | 2018-12-06T19:47:51Z | - |
dc.identifier.eissn | 1369-703X | por |
dc.identifier.doi | 10.1016/j.bej.2018.10.006 | por |
dc.description.publicationversion | info:eu-repo/semantics/publishedVersion | por |
dc.subject.wos | Science & Technology | por |
sdum.journal | Biochemical Engineering Journal | por |
Aparece nas coleções: | CEB - Publicações em Revistas/Séries Internacionais / Publications in International Journals/Series CBMA - Artigos/Papers DBio - Artigos/Papers |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
document_48989_1.pdf | 1,46 MB | Adobe PDF | Ver/Abrir |